CliffBio
small molecule

DAUNORUBICIN HYDROCHLORIDE

DAUNORUBICIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAUNORUBICIN HYDROCHLORIDE
Active ingredientDAUNORUBICIN HYDROCHLORIDE
StrengthEQ 5MG BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalNovember 2001
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.